Q3 Earnings Forecast for RXRX Issued By Leerink Partnrs

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) – Equities researchers at Leerink Partnrs lowered their Q3 2025 earnings per share estimates for shares of Recursion Pharmaceuticals in a research report issued on Wednesday, October 15th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($0.31) per share for the quarter, down from their prior estimate of ($0.24). The consensus estimate for Recursion Pharmaceuticals’ current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals’ Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($1.37) EPS.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The firm had revenue of $19.10 million for the quarter, compared to analyst estimates of $15.38 million. During the same period in the previous year, the company posted ($0.40) EPS. Recursion Pharmaceuticals’s revenue was up 33.3% on a year-over-year basis.

RXRX has been the topic of several other research reports. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Needham & Company LLC reissued a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $7.25.

Recursion Pharmaceuticals Price Performance

RXRX opened at $5.86 on Friday. The stock’s 50-day moving average price is $5.13 and its 200 day moving average price is $5.13. Recursion Pharmaceuticals has a 12-month low of $3.79 and a 12-month high of $12.36. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 0.02. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -3.29 and a beta of 0.91.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. TD Waterhouse Canada Inc. raised its position in shares of Recursion Pharmaceuticals by 64.1% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock worth $29,000 after acquiring an additional 2,200 shares in the last quarter. AlphaQuest LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth about $36,000. GAMMA Investing LLC raised its position in shares of Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after acquiring an additional 2,026 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of Recursion Pharmaceuticals by 97.2% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock worth $46,000 after acquiring an additional 4,446 shares in the last quarter. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter worth about $51,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Insider Activity

In other news, insider Najat Khan sold 36,599 shares of Recursion Pharmaceuticals stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the transaction, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. This trade represents a 5.19% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 8.43% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.